Skip to main content

3 Result(s)

within Isao Fujioka Remove this filter Pathology Remove this filter

and

  1. No Access

    Article

    Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis

    Treatment with a tyrosine kinase inhibitor (TKI) is the standard of care for patients with chronic myeloid leukemia (CML). The new-generation TKIs, nilotinib and dasatinib, are found to have deeper and faster ...

    Noriyoshi Iriyama, Kei-Ji Sugimoto, Eriko Sato, Tomoiku Takaku… in Medical Oncology (2018)

  2. No Access

    Article

    Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors

    We performed a retrospective study to evaluate the incidence of second malignancies (SMs) in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs). We analyzed data from 339 pa...

    Tomonori Nakazato, Noriyoshi Iriyama, Michihide Tokuhira, Maho Ishikawa… in Medical Oncology (2018)

  3. No Access

    Article

    Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase

    ABL1-tyrosine kinase inhibitors (TKIs) have led to dramatic changes in treatment strategies for chronic myeloid leukemia in the chronic phase (CML-CP). However, clinical studies have highlighted increasing num...

    Michihide Tokuhira, Yuta Kimura, Keiji Sugimoto, Tomonori Nakazato… in Medical Oncology (2018)